Executive Pool: 3911Companies: 69 - Players covered include Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; CapitalBio Technology Inc.; Cepheid Inc.; Fluidigm Corporation; Hoffman-La-Roche Ltd.; Illumina, Inc.; OcimumBiosolutions Ltd.; PerkinElmer, Inc.; Takara Bio Inc.; Takara Bio USA, Inc.; Thermo Fisher Scientific Inc. and Others.
Segments: Product Type (DNA Chip, Lab-on-a-Chip, Protein Chip, Other Product Types); Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, Other Applications)
Amid the COVID-19 crisis, the global market for Biochips estimated at US$15.9 Billion in the year 2022, is projected to reach a revised size of US$25.4 Billion by 2026, growing at a CAGR of 11.7% over the analysis period. DNA Chip, one of the segments analyzed in the report, is projected to grow at a 10.6% CAGR to reach US$9.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lab-On-a-chip segment is readjusted to a revised 12.3% CAGR for the next 7-year period. This segment currently accounts for a 30.6% share of the global Biochips market.
The U.S. Market is Estimated at $6.3 Billion in 2022, While China is Forecast to Reach $2.4 Billion by 2026
AXE Price at posting:
83.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)